Skip to Content

The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.

Equipoise Injectable (Canada)

This page contains information on Equipoise Injectable for veterinary use.
The information provided typically includes the following:
  • Equipoise Injectable Indications
  • Warnings and cautions for Equipoise Injectable
  • Direction and dosage information for Equipoise Injectable

Equipoise Injectable

This treatment applies to the following species:
Manufacturer: Pfizer



DIN 02223619

Veterinary Use Only

Net Contents: 50 mL


Active Ingredient: Each mL contains 50 mg boldenone undecylenate

Preservative: 3% w/v benzyl alcohol


EQUIPOISE injectable (boldenone undecylenate injection) is a long-acting injectable anabolic agent for horses, supplied in vials providing 50 mg boldenone undecylenate per mL in sesame oil with 3% (w/v) benzyl alcohol as a preservative.

Boldenone undecylenate is a steroid ester possessing marked anabolic properties and a small amount of androgenic activity.

Anabolic and androgenic agents have come to be widely used in the treatment of certain pathophysiological or catabolic processes in animals. In many instances, it is desirable to maintain a constant level of effect over a long period of time. Boldenone undecylenate is a long-acting injectable agent which has a rapid onset of action; this is advantageous and is preferred over frequent oral dosing or even repeated injections.


Anabolic agents are related to the sex hormones, but each varies in its anabolic and androgenic effect. Compounds such as methyltestosterone have anabolic activity, but with prolonged use, animals develop marked androgenic activity which makes these compounds unsuitable for prolonged therapy.

Studies conducted in laboratory animals to evaluate pharmacological activity characterized boldenone undecylenate as having distinct anabolic properties together with a certain degree of androgenic activity. It does not have marked antigonadotrophic properties, nor does it produce any clear-cut effects on the endometrium, conditions that are commonly observed when similar substances are used.

In clinical trials at the recommended dosage, EQUIPOISE injectable had a marked anabolic effect in debilitated horses, appetite improved, weight gain was noted, vigor increased and improvement was noted in musculature and haircoat. This would be expected with an anabolic agent such as EQUIPOISE injectable, particularly where there had been marked tissue breakdown associated with disease, prolonged anorexia or overwork.


Boldenone undecylenate is chemically known as 17ß-hydroxy-androsta-1,4-dien-


Equipoise Injectable Indications

EQUIPOISE injectable is recommended as an aid for treating debilitated horses when an improvement in weight, haircoat or general physical condition is desired. Debilitation often follows disease or may occur following overwork and over-exertion.

EQUIPOISE injectable improves the general state of debilitated horses, thus aiding in correcting weight losses and improving appetite. It is not a substitute for a well-balanced diet. Optimal results can be expected only when good management and feeding practices are utilized.

EQUIPOISE injectable should be considered only as adjunctive therapy to other specific and supportive therapy for diseases, surgical cases and traumatic injuries.


For horses only. This drug is not to be administered to horses that are to be slaughtered for use in food. Keep out of reach of children.


In the absence of data on the effect of boldenone undecylenate on immature colts and fillies, stallions, pregnant mares or brood mares during the breeding season, this drug should not be used in these animals.

Adverse Reactions

Treatment with EQUIPOISE injectable (boldenone undecylenate injection) may result in androgenic effects (masculinization, behavioural effects) being expressed in some animals. If these effects occur, they may persist for up to 6 to 8 weeks. No additional injections of boldenone undecylenate should be administered.


An overdose of EQUIPOISE injectable (boldenone undecylenate injection) may result in prolonged androgenic effects that make the horse difficult to handle. Should this occur, discontinue treatment until all signs of androgenicity disappear.

Equipoise Injectable Dosage And Administration

The dosage for horses is 0.28 to 1.10 mg/kg (0.13-0.5 mg/lb) of body weight intramuscularly. Treatment may be repeated every 2 to 3 weeks. The condition should be assessed by a veterinarian to determine the duration of treatment; however, most horses will respond with one or two treatments.


EQUIPOISE injectable (boldenone undecylenate injection) is available in multidose vials of 50 mL, providing 50 mg/mL boldenone undecylenate.


Store at room temperature, 15° - 30°C (59° - 86°F).

Avoid Freezing.

Wyeth Animal Health, Division of Wyeth Canada, Guelph, Ontario N1K 1E4

® Licensed user of Equipoise

Distributed by: Wyeth Canada, 1025 Marcel Laurin Blvd., St. Laurent, Quebec H4R 1J6



Nac No.

Pfizer Canada Inc.

Order Desk:   800-663-8888
Toll-Free:   877-633-2001
Technical Services Canada:   800-461-0917
Technical Services USA:   800-366-5288
Every effort has been made to ensure the accuracy of the Equipoise Injectable information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.

Copyright © 2018 North American Compendiums. Updated: 2018-05-30